Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug 21;20(7-8):538–548. doi: 10.1080/21678421.2019.1646769

Figure 3. Longitudinal changes in serum pNfH concentrations (pg/ml).

Figure 3.

(A) Controls; (B) at-risk individuals who remain pre-symptomatic throughout follow-up; (C) phenoconverters; and (D) ALS patients. The x-axis in (A) and (B) shows years since baseline. The x-axis in (C) and (D) shows years to or since the onset of symptoms/signs, which is marked by the vertical dashed line at year = 0. ALS = amyotrophic lateral sclerosis; pNfH = phosphorylated neurofilament heavy. Shading indicates the 95th percentile of all available data among controls.